Last edition
News about "Seralutinib "
Gossamer Bio Submits First NDA for Seralutinib in PAH
Gossamer Bio has filed an NDA for seralutinib, supported by Phase 3 PROSERA and Phase 2 TORREY study data.
Seralutinib | 25/09/2026 | By News Bureau | 105
Gossamer Bio Partners with Chiesi to Develop and Commercialize Seralutinib
Gossamer Bio, Inc. has signed a global collaboration and license deal with Chiesi Farmaceutici to develop and commercialize seralutinib.
Seralutinib | 07/05/2024 | By Aishwarya | 422
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy